Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2017

01-01-2017 | Bone and Soft Tissue Sarcomas

Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor

Authors: Ser Yee Lee, MD, MSc, MMed, FRCS(Ed), Brian K. P. Goh, MBBS, MSc, MMed, FRCS(Ed), Eran Sadot, MD, Rahul Rajeev, MBBS, Vinod P. Balachandran, MD, Mithat Gönen, PhD, T. Peter Kingham, MD, Peter J. Allen, MD, Michael I. D’Angelica, MD, William R. Jarnagin, MD, Daniel Coit, MD, Wai Keong Wong, MBBS, FRCS, Hock Soo Ong, MBBS, FRCS, Alexander Y. F. Chung, MBBS, FRCS, Ronald P. DeMatteo, MD

Published in: Annals of Surgical Oncology | Issue 1/2017

Login to get access

Abstract

Background

The surgical management of duodenal gastrointestinal stromal tumors (DGIST) is poorly characterized. Limited resection may be technically feasible and oncologically safe, but anatomic considerations may compromise the resection margins due to the proximity of critical structures, thereby necessitating more extensive resections such as pancreaticoduodenectomy.

Methods

Patients undergoing surgery for DGIST at two institutions from 1994 to 2014 were identified. Clinicopathologic and survival data were analyzed to compare outcomes in patients treated with limited or radical resection.

Results

Sixty patients underwent surgery for DGIST. Pancreaticoduodenectomy was performed in 38 % while the rest underwent limited resections. The most common type of limited resection was wedge resection and primary closure (49 %) followed by segmental resection with an end-to-end or side-to-side duodenojejunostomy (27 %). The pancreaticoduodenectomy group tended to have larger tumors with the majority located in D2/3 (87 %) and at the mesenteric border (91 %). The pancreaticoduodenectomy group also had significantly greater intraoperative blood loss, longer operative time, longer hospital stay, and higher 90-day morbidity and readmission rates. The 5-year relapse-free survival, recurrence-free survival, and overall survival for the pancreaticoduodenectomy versus limited resection were 81 versus 56 % (p = 0.05), 64 versus 53 % (p = 0.5), and 76 versus 72 % (p = 0.6), respectively. A surgical algorithm based on the location and size of the tumor is proposed.

Conclusions

Limited resection of DGIST is safe, but may be associated with lower 5-year relapse-free survival. Pancreaticoduodenectomy is recommended for selected patients with DGIST when an R0 resection cannot be performed without removing the ampulla or part of the pancreas.
Literature
1.
Joensuu H, DeMatteo RP. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med. 2012;63:247–58.CrossRefPubMed
2.
Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–25.CrossRefPubMed
3.
Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol. 2002;33:484–95.CrossRefPubMed
4.
DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–8.CrossRefPubMedPubMedCentral
5.
6.
Zhou B, Zhang M, Wu J, et al. Pancreaticoduodenectomy versus local resection in the treatment of gastrointestinal stromal tumors of the duodenum. World J Surg Oncol. 2013;11:196.CrossRefPubMedPubMedCentral
7.
Bourgouin S, Hornez E, Guiramand J, et al. Duodenal gastrointestinal stromal tumors (GISTs): arguments for conservative surgery. J Gastrointest Surg. 2013;17:482–7.CrossRefPubMed
8.
Tien YW, Lee CY, Huang CC, et al. Surgery for gastrointestinal stromal tumors of the duodenum. Ann Surg Oncol. 2010;17:109–14.CrossRefPubMed
9.
Goh BK, Chow PK, Kesavan S, et al. Outcome after surgical treatment of suspected gastrointestinal stromal tumors involving the duodenum: is limited resection appropriate? J Surg Oncol. 2008;97:388–91.CrossRefPubMed
10.
Goh BK, Chow PK, Ong HS, et al. Gastrointestinal stromal tumor involving the second and third portion of the duodenum: treatment by partial duodenectomy and Roux-en-Y duodenojejunostomy. J Surg Oncol. 2005;91:273–5.CrossRefPubMed
11.
Chok AY, Koh YX, Ow MY, et al. A systematic review and meta-analysis comparing pancreaticoduodenectomy versus limited resection for duodenal gastrointestinal stromal tumors. Ann Surg Oncol. 2014;21:3429–38.CrossRefPubMed
12.
El-Gendi A, El-Gendi S, El-Gendi M. Feasibility and oncological outcomes of limited duodenal resection in patients with primary nonmetastatic duodenal GIST. J Gastrointest Surg. 2012;16:2197–202.CrossRefPubMed
13.
Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.CrossRefPubMed
14.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
15.
Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097–104.CrossRefPubMedPubMedCentral
16.
Fischer M, Matsuo K, Gonen M, et al. Relationship between intraoperative fluid administration and perioperative outcome after pancreaticoduodenectomy: results of a prospective randomized trial of acute normovolemic hemodilution compared with standard intraoperative management. Ann Surg. 2010;252:952–8.CrossRefPubMed
17.
Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65.CrossRefPubMed
18.
Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466–78.PubMed
19.
Uchida H, Sasaki A, Iwaki K, et al. An extramural gastrointestinal stromal tumor of the duodenum mimicking a pancreatic head tumor. J Hepatobiliary Pancreat Surg. 2005;12:324–7.CrossRefPubMed
20.
Johnston FM, Kneuertz PJ, Cameron JL, et al. Presentation and management of gastrointestinal stromal tumors of the duodenum: a multi-institutional analysis. Ann Surg Oncol. 2012;19:3351–60.CrossRefPubMed
21.
Colombo C, Ronellenfitsch U, Yuxin Z, et al. Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center study. Ann Surg Oncol. 2012;19:3361–7.CrossRefPubMed
22.
Miettinen M, Kopczynski J, Makhlouf HR, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol. 2003;27:625–41.CrossRefPubMed
23.
24.
Duffaud F, Meeus P, Bachet JB, et al. Conservative surgery vs duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors (GIST): a retrospective review of 114 patients from the French sarcoma group (FSG). Eur J Surg Oncol. 2014;40:1369–75.CrossRefPubMed
25.
Koh YX, Chok AY, Zheng HL, et al. A systematic review and meta-analysis comparing laparoscopic versus open gastric resections for gastrointestinal stromal tumors of the stomach. Ann Surg Oncol. 2013;20:3549–60.CrossRefPubMed
26.
Karakousis GC, Singer S, Zheng J, et al. Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors (GISTs): a size-matched comparison. Ann Surg Oncol. 2011;18:1599–605.CrossRefPubMedPubMedCentral
27.
Cavallaro G, Polistena A, D’Ermo G, et al. Duodenal gastrointestinal stromal tumors: review on clinical and surgical aspects. Int J Surg. 2012;10:463–5.CrossRefPubMed
28.
Yamashita S, Sakamoto Y, Saiura A, et al. Pancreas-sparing duodenectomy for gastrointestinal stromal tumor. Am J Surg. 2014;207:578–83.CrossRefPubMed
29.
Winfield RD, Hochwald SN, Vogel SB, et al. Presentation and management of gastrointestinal stromal tumors of the duodenum. Am Surg. 2006;72:719–22.PubMed
30.
McCarter MD, Antonescu CR, Ballman KV, et al. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg. 2012;215:53–9.CrossRefPubMedPubMedCentral
31.
Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol. 2012;19:1074–80.CrossRefPubMed
32.
Rutkowski P, Gronchi A, Hohenberger P, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol. 2013;20:2937–43.CrossRefPubMed
33.
Hohenberger P, Eisenberg B. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST). Ann Surg Oncol. 2010;17:2585–600.CrossRefPubMed
34.
Eisenberg BL, Trent JC. Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int J Cancer. 2011;129:2533–42.CrossRefPubMed
Metadata
Title
Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor
Authors
Ser Yee Lee, MD, MSc, MMed, FRCS(Ed)
Brian K. P. Goh, MBBS, MSc, MMed, FRCS(Ed)
Eran Sadot, MD
Rahul Rajeev, MBBS
Vinod P. Balachandran, MD
Mithat Gönen, PhD
T. Peter Kingham, MD
Peter J. Allen, MD
Michael I. D’Angelica, MD
William R. Jarnagin, MD
Daniel Coit, MD
Wai Keong Wong, MBBS, FRCS
Hock Soo Ong, MBBS, FRCS
Alexander Y. F. Chung, MBBS, FRCS
Ronald P. DeMatteo, MD
Publication date
01-01-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 1/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5565-9

Other articles of this Issue 1/2017

Annals of Surgical Oncology 1/2017 Go to the issue

Colorectal Cancer

“Adjuvant” Hyperthermic Intraperitoneal Chemotherapy: A Call to Action

Melanomas

Editorial: Should We Abandon TNM Staging in Favor of Gene Profiles in Node-Positive Melanoma?

Gastrointestinal Oncology

Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case–Control Study

Thoracic Oncology

Transthoracic Anastomotic Leak After Esophagectomy: Current Trends

Bone and Soft Tissue Sarcomas

Tailoring Surgical Therapy for Extremity Soft Tissue Sarcoma

Colorectal Cancer

Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer